Artemether
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Artemether
- Artemether: From WHO-Recommended Antimalarial to Plasmodium falciparum Malaria in South Africa
Artemether: From WHO-Recommended Antimalarial to Plasmodium falciparum Malaria in South Africa
One-Sentence Summary
Artemether is an artemisinin derivative and core component of artemether-lumefantrine (Coartem®), the WHO first-line combination therapy for uncomplicated malaria — yet it holds zero SAHPRA registrations in South Africa. The TxGNN model confirms Plasmodium falciparum Malaria as its primary actionable prediction (rank 2, score 99.77%), supported by 10+ completed Phase 3/4 RCTs and 20 publications, including multiple Cochrane systematic reviews. The highest-ranked prediction (acquired angioedema, rank 1, score 99.99%) has been identified as a knowledge graph false positive with no supporting clinical evidence and is not recommended for further evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | WHO first-line antimalarial; artemether-lumefantrine (AL/Coartem®) is the global standard of care for uncomplicated Plasmodium falciparum malaria |
| Predicted New Indication | Plasmodium falciparum malaria |
| TxGNN Prediction Score | 99.77% (rank 2) |
| Evidence Level | L1 |
| South Africa Market Status | Not marketed in South Africa |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Artemether contains an endoperoxide bridge that, upon entering parasitised erythrocytes, reacts with ferrous iron (Fe²⁺) released during haemoglobin degradation. This reaction generates carbon-centred free radicals and reactive oxygen species (ROS) that directly damage P. falciparum proteins, lipids, and cell membranes. A secondary mechanism involves inhibition of PfATP6 — a P. falciparum-specific SERCA-like Ca²⁺-ATPase — which disrupts parasite calcium homeostasis. Critically, the selectivity of this mechanism for parasitised (iron-rich) cells over healthy human erythrocytes explains the drug’s therapeutic window.
The ROS-generating endoperoxide mechanism is effective across multiple Plasmodium species (P. falciparum, P. vivax, P. ovale, P. malariae), making artemether a broad-spectrum antimalarial. This mechanistic breadth is validated by two independent Cochrane systematic reviews (PMID 31210357, 25209020) and by the WHO’s designation of artemether-lumefantrine as first-line therapy in 86 countries, including 30 of 47 sub-Saharan African nations.
Despite this global evidence base, artemether carries zero SAHPRA registrations in South Africa. This creates a regulatory gap in a country where malaria remains endemic in Limpopo, Mpumalanga, and KwaZulu-Natal, and where the National Department of Health already recommends artemether-lumefantrine as standard of care. Formalising SAHPRA registration would strengthen supply chain assurance, enable structured pharmacovigilance, and support rational prescribing — particularly important given South Africa’s significant HIV/malaria co-infection burden and the well-documented pharmacokinetic interactions between AL and antiretroviral therapy.
Note on Rank 1 Prediction: Acquired Angioedema
Assessment: False Positive — Do Not Pursue
TxGNN assigned its highest score (99.99%) to acquired angioedema (AAE). AAE is caused by acquired C1-esterase inhibitor deficiency (typically secondary to B-cell malignancy or autoantibodies), leading to bradykinin accumulation and increased vascular permeability. Artemether’s mechanism — ROS generation and PfATP6 inhibition — has no connection to the complement pathway or bradykinin system. There are zero clinical trials and zero publications supporting this use. The high TxGNN score is attributed to structural clustering of angioedema-class nodes in the knowledge graph rather than pharmacological relevance. Predictions for angioedema (ranks 1, 4, 5, 10) all carry the same false-positive signature and are uniformly recommended as Hold.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05842954 | Phase 3 | Completed | 1,720 | KLU156 (ganaplacide + lumefantrine-SDF) vs. Coartem® as active comparator in adults and children ≥10 kg with uncomplicated P. falciparum malaria; large-scale validation of AL as the standard benchmark |
| NCT01651416 | Phase 4 | Completed | 2,400 | Seasonal malaria chemoprevention vs. long-acting artemisinin combination therapy for prevention of malaria and anaemia in children in extended transmission settings, Ghana |
| NCT00885287 | Phase 4 | Completed | 830 | Therapeutic efficacy, safety, and pharmacokinetic interactions of artemether-lumefantrine with nevirapine-based antiretrovirals in HIV-infected patients with uncomplicated falciparum malaria, Tanzania — directly relevant to South Africa’s HIV co-infection context |
| NCT00344006 | Phase 3 | Completed | 1,395 | Multicentre double-blind double-dummy RCT: chlorproguanil-dapsone-artesunate vs. artemether-lumefantrine in children and adolescents with uncomplicated P. falciparum malaria across Africa |
| NCT00316329 | Phase 3 | Completed | 1,032 | Multinational RCT comparing artesunate-amodiaquine (once or twice daily dosing) vs. Coartem® for uncomplicated P. falciparum malaria; non-inferiority design across multiple African sites |
| NCT01845701 | Phase 3 | Completed | 720 | 42-day follow-up comparing artesunate-amodiaquine and dihydroartemisinin-piperaquine vs. artemether-lumefantrine in children with P. falciparum malaria in two ecological zones, Cameroon |
| NCT01916954 | Phase 3 | Completed | 96 | Direct comparison of two AL dosing regimens for P. falciparum treatment in pregnant women, Democratic Republic of Congo; addresses special population safety gap |
| NCT00540410 | Phase 4 | Completed | 366 | Head-to-head RCT: artesunate+amodiaquine vs. artemether+lumefantrine for repeated uncomplicated P. falciparum episodes over 2 years, Senegal; includes QTc cardiac tolerability assessment |
| NCT00529867 | Phase 4 | Completed | 267 | AL suspension vs. tablets in children aged 6–59 months with uncomplicated P. falciparum malaria, Kenya; paediatric formulation comparison directly relevant to child dosing |
| NCT02090036 | Phase 4 | Completed | 220 | Efficacy and safety of single low-dose primaquine added to standard AL for P. falciparum gametocyte clearance; supports AL as platform for transmission-blocking strategies |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35271592 | 2022 | Systematic Review & Meta-analysis | PLoS One | Therapeutic efficacy of AL, ASAQ, and DHA-PQ for uncomplicated P. falciparum in Sub-Saharan Africa; confirms AL as consistently effective first-line ACT |
| 31210357 | 2019 | Cochrane Systematic Review | Cochrane Database Syst Rev | Intramuscular artemether vs. quinine and artesunate for severe malaria; supports artemether efficacy in severe disease |
| 25209020 | 2014 | Cochrane Systematic Review | Cochrane Database Syst Rev | Earlier Cochrane review confirming artemether vs. quinine for severe malaria; foundational evidence base |
| 37979594 | 2023 | RCT | Lancet | PRIMA trial: primaquine radical cure in P. falciparum/P. vivax co-endemic settings; AL used as ACT backbone — demonstrates AL’s role in combination strategies |
| 38705163 | 2024 | Phase 2 RCT | Lancet Microbe | AL ± single-dose primaquine vs. SP+amodiaquine ± tafenoquine for gametocyte carriage reduction and transmission blockade, Mali |
| 34384431 | 2021 | Systematic Review & Meta-analysis | Malaria Journal | DHA-PQ vs. AL efficacy for uncomplicated P. falciparum in Africa; AL remains the well-characterised standard comparator |
| 34983552 | 2022 | Systematic Review & Meta-analysis | Malaria Journal | Comprehensive safety comparison of DHA-PQ vs. AL for uncomplicated P. falciparum in African children; AL safety profile well-documented |
| 33957925 | 2021 | Systematic Review & Meta-analysis | Malaria Journal | Efficacy and safety of AL for uncomplicated P. falciparum in Ethiopia; high PCR-corrected cure rates across multiple studies |
| 22548983 | 2012 | Systematic Review | Malaria Journal | Safety and efficacy of AL for uncomplicated P. falciparum during pregnancy; underpins WHO recommendation for second/third trimester use |
| 23419113 | 2013 | Expert Review | Expert Opin Pharmacother | AL for uncomplicated P. falciparum in sub-Saharan Africa; approved in 86 countries, first-line in 30/47 sub-Saharan African countries — contextualises the SA registration gap |
South Africa Market Information
Artemether is currently not registered with SAHPRA and there are no approved products on the South African market.
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | No SAHPRA-registered products | — | — |
Practical context for South African prescribers:
- Access to artemether-lumefantrine (Coartem®) in South Africa currently occurs via:
- Section 21 authorisation (unregistered medicine access, SAHPRA approval required per patient or per programme)
- Government procurement through National Department of Health malaria programmes aligned with WHO/Global Fund supply channels
- Artemether-lumefantrine is included on the WHO Essential Medicines List and the South African Essential Drugs Programme (EDP) formulary for use in malaria-endemic provinces (Limpopo, Mpumalanga, KwaZulu-Natal)
- Formal SAHPRA registration would enable routine commercial availability, structured pharmacovigilance, and inclusion in provincial formularies
Safety Considerations
Detailed SAHPRA-specific safety labelling data are not available in this evidence pack. Based on global clinical trial data, the following are clinically important for the South African context:
Drug Interactions (particularly relevant given South Africa’s HIV/malaria co-infection burden):
- Artemether-lumefantrine is metabolised via CYP3A4 (artemether) and CYP3A4/CYP2D6 (lumefantrine)
- Efavirenz: reduces lumefantrine AUC by approximately 50% — standard AL dosing may be insufficient in HIV patients on efavirenz-based ART; double-dose AL or alternative ACT should be considered
- Nevirapine: reduces lumefantrine exposure by approximately 40%
- Ritonavir-boosted protease inhibitors (e.g., lopinavir/ritonavir): may increase lumefantrine exposure and QTc prolongation risk
- QTc-prolonging agents: AL prolongs the QTc interval; avoid concurrent use with other QTc-prolonging drugs (antifungals, fluoroquinolones, antipsychotics)
Please refer to the SAHPRA-approved Professional Information (PI) for complete safety information once registered. Report suspected adverse drug reactions to SAHPRA using the MedSafety online reporting system (www.sahpra.org.za).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Artemether-lumefantrine has overwhelming L1 evidence — multiple completed Phase 3/4 RCTs enrolling thousands of patients and two independent Cochrane systematic reviews — confirming efficacy and safety for Plasmodium falciparum malaria across sub-Saharan Africa. It is already recommended by South Africa’s National Department of Health and administered in malaria-endemic provinces, but the absence of formal SAHPRA registration creates a pharmacovigilance blind spot, supply chain vulnerability, and prescribing uncertainty — all of which formal registration would address.
To proceed, the following is needed:
- SAHPRA registration application: submit a complete Common Technical Document (CTD) dossier for artemether-lumefantrine fixed-dose combination, including quality, safety, and efficacy modules; bioequivalence/PK data
- South Africa-specific Professional Information (PI): develop SAHPRA-compliant labelling addressing key SA-relevant concerns — antiretroviral drug interactions (efavirenz, nevirapine, ritonavir), pregnancy safety, and G6PD deficiency guidance
- HIV/malaria co-infection sub-study data: formal review or prospective data collection on AL dosing strategies in South African patients on efavirenz- or nevirapine-based ART (Limpopo, Mpumalanga, KwaZulu-Natal enrolment sites recommended)
- Pharmacovigilance plan: establish structured ADR monitoring and reporting through SAHPRA’s MedSafety system for all malaria-endemic provinces
- EML formal listing: pursue inclusion on national and provincial Essential Medicines Lists with specific malaria-endemic province formulary entries to ensure equitable access and procurement visibility
Disclaimer: This report is generated for research and drug repurposing evaluation purposes only and does not constitute medical advice or a prescribing recommendation. Drug repurposing predictions from the TxGNN model are investigational and require clinical validation before therapeutic application. All prescribing decisions must be based on current SAHPRA-approved Professional Information and applicable South African treatment guidelines. This report does not replace clinical judgement.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.